Authors
Nour M Alkashef, Ammar A Khan, Mohamed N Seleem
Published in
PLoS neglected tropical diseases. Volume 20. Issue 8. Pages e0014627. Epub Aug 17, 2026.
Abstract
Cryptococcosis is a major health threat among immunocompromised individuals, resulting in life-threatening consequences secondary to brain invasion. The limited treatment options and the increased incidence of treatment failure and relapses urge the need for more effective therapies. In this study, we investigated the therapeutic potential of nitroxoline (NTX) in treating cryptococcal infection. NTX exhibited potent fungicidal activity against Cryptococcus neoformans/gattii clinical isolates, with an MIC90 of 1 µg/mL. In addition, NTX substantially inhibits the main virulence traits of cryptococcal cells, including the polysaccharide capsule, melanin production, and the urease enzyme, which are crucial for the infection progression. In exploring the potential mechanism of action, our results revealed the relationship between the metal-chelating properties of the NTX scaffold and its antifungal activity. Interfering metal chelation, either through structural modification or exogenous supplementation with varied divalent cations, significantly reduced the antifungal and anti-virulence activities of NTX. Given its potential therapeutic role, we evaluated the interaction between NTX and the clinically used antifungals amphotericin B, flucytosine and fluconazole. Additionally, we investigated the tendency of cryptococcal cells to develop resistance following repeated exposure to NTX, as well as its efficacy in the Caenorhabditis elegans nematode model of cryptococcal infection. Notably, cryptococcal cells exhibited consistent susceptibility to NTX upon repeated exposure to a subinhibitory concentration. In the C. elegans model, NTX significantly reduced the fungal burden of the infected worms, achieving a 2-log10 reduction, and consistently enhanced their survival compared to untreated group. These findings highlight the potential role of the NTX scaffold in combating cryptococcal infection that warrants further investigation.
PMID:
42607071
Bibliographic data and abstract were imported from PubMed on 18 Aug 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 16
- Comments 0